IBD biologic and small-molecule landscape, 2026 mid-year reference
Reference layout of the IBD therapeutic class as of mid-2026: approved biologics (anti-TNF, anti-integrin, IL-12/23, IL-23), oral small molecules (JAK, S1P modulators, TYK2 in pipeline), and the live commercial questions including line-of-therapy positioning and combination strategy.
Reference layout of the IBD biologic and small-molecule landscape as of mid-2026. Includes approved biologics across anti-TNF, anti-integrin, IL-12/23 and IL-23 mechanisms, oral small molecules (JAK, S1P modulators), and the live commercial questions including line-of-therapy positioning, combination strategy, and the next-generation pipeline. Useful as a quick orientation as the IBD therapeutic landscape moves from anti-TNF-first-line dominance to multi-mechanism first-line decision-making.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- ExplainedWhat is lupus nephritis?